Abstract
Current PDT agents often suffer from low singlet oxygen quantum yields, photobleaching, and poor biocompatibility. To address these issues, we propose novel PDT agents that combine the synthesized phthalocyanines with cysteine-functionalized graphene quantum dots (cys-GQDs) for the first time. This combination aims to enhance singlet oxygen production and improve solubility in biological media. In this way, new zinc phthalocyanines with halogen substituents were synthesized for potential use in photodynamic therapy (PDT). Specifically, 2-Bromo-4-methylphenol zinc (II) phthalocyanine (2a) and 2-chloro-4-methylphenol zinc(II) phthalocyanine (2b) and their graphene quantum dots derivatives were synthesized and characterized. The photochemical, sonochemical, and sono-photochemical properties of these compounds were analyzed, focusing on their efficiency in singlet oxygen production. Our studies of the 2a@cys-GQDs and 2b@cys-GQDs conjugates demonstrated higher singlet oxygen yields, suggesting their enhanced potential for clinical applications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Photochemistry & Photobiology, A: Chemistry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
